NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti - PD-1 therapy: MASTERKEY-115, 1,2
Robert, Caroline
Gastman, Brian
Gogas, Helen
Rutkowski, Piotr
V. Long, Georgina
Chaney, Marya F.
Joshi, Harshada
Lin, Yu-Lin
Snyder, Wendy
Chesney, Jason A.
EUROPEAN JOURNAL OF CANCER, 2024, 207
[42] Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Guo, Y.
Ahn, M-J
Chan, A.
Wang, C-H
Kang, J-H
Kim, S-B
Bello, M.
Arora, R. S.
Zhang, Q.
He, X.
Li, P.
Dechaphunkul, A.
Kumar, V
Kamble, K.
Li, W.
Kandil, A.
Cohen, E. E. W.
Geng, Y.
Zografos, E.
Tang, P. Z.
ANNALS OF ONCOLOGY, 2019, 30 (11) : 1831 - 1839
[43] Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Liu, Si-Yang
Dong, Song
Yang, Xue-Ning
Liao, Ri-Qiang
Jiang, Ben-Yuan
Wang, Qun
Ben, Xiao-Song
Qiao, Gui-Bin
Lin, Jun-Tao
Yan, Hong-Hong
Yan, Li-Xu
Nie, Qiang
Tu, Hai-Yan
Wang, Bin-Chao
Yang, Jin-Ji
Zhou, Qing
Li, Hong-Rui
Liu, Ke
Wu, Wendy
Liu, Si-Yang Maggie
Zhong, Wen-Zhao
Wu, Yi-Long
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[44] Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
Kadono, Yoshifumi
Konaka, Hiroyuki
Izumi, Kouji
Anai, Satoshi
Fujimoto, Kiyohide
Ishibashi, Kei
Kawai, Noriyasu
Kato, Taku
Iba, Akinori
Masumori, Naoya
Yoshimura, Kenichi
Mizokami, Atsushiu
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
[45] A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
Li, D.
Pant, S.
Ryan, D. P.
Laheru, D.
Bahary, N.
Dragovich, T.
Hosein, P. J.
Rolfe, L.
Saif, M. W.
LaValle, J.
Yu, K. H.
Lowery, M. A.
Allen, A.
O'Reilly, E. M.
PANCREATOLOGY, 2014, 14 (05) : 398 - 402
[46] Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
Chung, Christine H.
Bonomi, Marcelo
Steuer, Conor E.
Li, Jiannong
Bhateja, Priyanka
Johnson, Matthew
Masannat, Jude
Song, Feifei
Hernandez-Prera, Juan C.
Wenig, Bruce M.
Molina, Helen
Farinhas, Joaquim M.
McMullen, Caitlin P.
Wadsworth, J. Trad
Patel, Krupal B.
Kish, Julie A.
Muzaffar, Jameel
Kirtane, Kedar
Rocco, James W.
Schell, Michael J.
Saba, Nabil F.
CANCERS, 2021, 13 (05) : 1 - 16
[47] Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Felip, Enriqueta
de Braud, Filippo G.
Maur, Michela
Loong, Herbert H.
Shaw, Alice Tsang
Vansteenkiste, Johan F.
John, Thomas
Liu, Geoffrey
Lolkema, Martijn P.
Selvaggi, Giovanni
Giannone, Vanessa
Cazorla, Pilar
Baum, Jason
Balbin, O. Alejandro
Wang, Luojun
Lau, Yvonne Y.
Scott, Jeffrey W.
Tan, Daniel Shao-Weng
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 392 - 403
[48] A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, Matthew
Allan, Stephanie
Conway, Hannah
Boucher, Kenneth
Marvin, James
Hawks, Josiah
Burnett, William
Van Brocklin, Matthew
Whisenant, Jonathan
Gilcrease, Glynn
Gupta, Sumati
BMC RESEARCH NOTES, 2023, 16 (01)
[49] Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
Ribas, Antoni
Kirkwood, John M.
Atkins, Michael B.
Whiteside, Theresa L.
Gooding, William
Kovar, Andreas
Gillies, Stephen D.
Kashala, Oscar
Morse, Michael A.
JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
[50] A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Matthew Gumbleton
Stephanie Allan
Hannah Conway
Kenneth Boucher
James Marvin
Josiah Hawks
William Burnett
Matthew Van Brocklin
Jonathan Whisenant
Glynn Gilcrease
Sumati Gupta
BMC Research Notes, 16

← 1 2 3 4 5 →